Logo image
Anaesthetic Management of a Patient With Immune-Mediated Necrotizing Muscle Disease With the Use of a Novel Ultrashort-Acting Benzodiazepine, Remimazolam: A Case Report
Journal article   Open access   Peer reviewed

Anaesthetic Management of a Patient With Immune-Mediated Necrotizing Muscle Disease With the Use of a Novel Ultrashort-Acting Benzodiazepine, Remimazolam: A Case Report

Hitoshi Ogino, Daisuke Sugiyama and Kenichi Ueda
Curēus (Palo Alto, CA), Vol.15(4), e37326
04/09/2023
DOI: 10.7759/cureus.37326
PMCID: PMC10168013
PMID: 37182089
url
https://doi.org/10.7759/cureus.37326View
Published (Version of record) Open Access

Abstract

We reported the anesthetic management of remimazolam, a novel ultra-short-acting benzodiazepine, for a 21-month-old female with immune-mediated necrotizing myopathy (IMNM). Remimazolam has a similar chemical structure to midazolam but possesses a unique side chain that reduces its propensity to accumulate in the body, thereby minimizing prolonged sedation or respiratory depression. Our experience supports that remimazolam could be a suitable agent for anesthetizing the patient with IMNM.
General & Internal Medicine Life Sciences & Biomedicine Medicine, General & Internal Science & Technology

Details

Metrics

Logo image